Advertisement
ABT vs SYK
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Abbott Laboratories (ABT) is a diversified healthcare company spanning medical devices, diagnostics, nutrition, and established pharmaceuticals, while Stryker (SYK) is a pure-play medical technology leader in orthopaedics and surgical equipment.
- Both stocks have lagged the broader market in recent months, with ABT trading well below its 52-week high and SYK down roughly 21% year to date.
- Abbott's momentum has been driven by medical devices and its Exact Sciences acquisition, while Stryker is rebounding from a first-quarter cybersecurity disruption.
- Stryker carries a higher forward earnings multiple but a lower dividend yield than Abbott, reflecting differing growth and income profiles.
- Relative positioning favors Abbott on diversification and income, and Stryker on focused operating-margin strength and robotics-led growth.
Introduction
Medical technology remains one of the most closely watched corners of the healthcare sector, and few pairings illustrate its breadth better than ABT and SYK. Abbott Laboratories is a diversified healthcare giant whose reach extends well beyond devices into diagnostics and branded generics, while Stryker is a focused orthopaedics and surgical-technology franchise. For investors weighing a broad healthcare conglomerate against a high-margin medtech specialist, this stock comparison offers a useful lens on growth drivers, risk factors, and relative performance. The contrast is especially relevant in the current environment, where both names have faced distinct operational pressures even as underlying demand for their products remains broadly healthy.
ABT Overview and Recent Performance
Abbott Laboratories operates four core businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. Recent market activity has been defined by two forces pulling in opposite directions. On the upside, the company's medical devices segment, led by diabetes care and electrophysiology, has sustained solid growth, and the March 2026 completion of its roughly $20 billion acquisition of Exact Sciences established a high-growth cancer diagnostics franchise. In its most recent reported quarter, Abbott delivered mid-teens revenue growth and raised its full-year adjusted earnings guidance, supported by double-digit growth in the newly added cancer testing business.
Offsetting that momentum, Abbott's nutrition segment has continued to face softer volumes following strategic pricing actions, and growth in its continuous glucose monitor (CGM) franchise decelerated from prior double-digit rates. Those concerns weighed on sentiment in recent months, and the shares have traded well below their 52-week high. Abbott also carries a lower forward earnings multiple and a dividend yield of roughly 2.5%, which reflects its diversified, income-oriented profile rather than a pure growth premium.
SYK Overview and Recent Performance
Stryker Corporation is a medical technology company concentrated in orthopaedics and MedSurg & Neurotechnology, with a leadership position in operating-room equipment and a growing surgical-robotics platform built around its Mako system. Recent performance has been shaped heavily by a March 2026 cybersecurity incident that temporarily disrupted ordering, shipping, and manufacturing, driving a sharp slowdown in first-quarter sales. By the second quarter, operations had largely normalized: organic sales growth rebounded to roughly 9%, and adjusted earnings rose nearly 18% year over year on expanding margins.
Stryker's recovery has been broad, with record Mako installations and strength across trauma, endoscopy, and medical equipment. The company also announced a planned CEO transition, with long-time leader Kevin Lobo moving to Executive Chair and President Scott Stiles becoming chief executive in 2027. Despite the operational rebound, shares remain down meaningfully year to date, and the stock trades below its five-year median forward earnings multiple. Stryker's focused portfolio supports an adjusted operating margin in the mid-20s, though its dividend yield is a comparatively modest 1.3%.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI trading bots that collectively monitor thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and basket of securities. Because market conditions shift constantly, not every bot is equally suited to the current environment. The Trending AI Robots section is designed to surface only those strategies that are best aligned with prevailing market conditions, helping users focus on the most relevant signals rather than the full universe. Explore the Trending AI Robots page to review the currently featured strategies and their performance metrics.
Head-to-Head Comparison
The core trade-off between these two stocks is diversification versus focus. Abbott spreads its revenue across devices, diagnostics, nutrition, and pharmaceuticals, which can cushion weakness in any single business but also dilutes the impact of its fastest-growing segments. Stryker, by contrast, concentrates on high-margin orthopaedic and surgical technologies, giving it greater exposure to procedural volumes and capital-equipment spending cycles.
On growth drivers, Abbott's story leans on device innovation such as the Libre Duo glucose-ketone sensor and the newly acquired cancer diagnostics portfolio, while Stryker's hinges on Mako robotics adoption and new product launches across joint replacement and trauma. In terms of recent momentum, both companies reported improving second-quarter results, but Stryker's rebound was partly a recovery from a one-time cyber disruption, whereas Abbott's acceleration was more organic in nature.
Risk profiles also differ. Abbott faces ongoing nutrition softness and CGM competitive pressures, while Stryker contends with cyber remediation costs, a peripheral vascular supply disruption, and acquisition integration. On valuation, Stryker's forward earnings multiple sits modestly above Abbott's, but its significantly higher operating margin and focused growth profile help justify that premium. For income-oriented investors, Abbott's higher dividend yield is a clear differentiator.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI would likely lean toward ABT in the current environment. Abbott's diversified revenue base, improving organic momentum, and higher dividend yield offer a steadier trend profile, while its lower forward multiple suggests less demanding expectations. Stryker's focused growth and superior margins are compelling, but its recent performance has been more volatile due to the cyber disruption and pending leadership transition, introducing greater short-term uncertainty. The verdict is probabilistic rather than definitive: a diversified, income-supported name with accelerating growth currently presents the more favorable risk-adjusted setup, though Stryker remains a strong candidate for investors seeking concentrated medtech exposure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Hold and SYK is a StrongBuy.
ABT in +2.49% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABT advanced for three days, in 172 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Indicator exited the oversold zone, 18 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 49%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 25 of 54 cases over the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 54 cases where ABT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.403) is normal, around the industry mean (2.874). P/E Ratio (32.423) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.025) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
SYK in upward trend: price rose above 50-day moving average on October 20, 2026
SYK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 24 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SYK as a result. In 48 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 23 of 44 cases over the following month. The odds of a continued upward trend are 52%.
Following a +3.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 171 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SYK entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.759) is normal, around the industry mean (2.874). P/E Ratio (30.586) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.012) settles around the average of (0.009) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ABT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 76 | |
SMR RATING 1..100 | 68 | 52 | |
PRICE GROWTH RATING 1..100 | 55 | 56 | |
P/E GROWTH RATING 1..100 | 5 | 83 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABT's Valuation (70) in the Medical Specialties industry is in the same range as SYK (76). This means that ABT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (76) in the Medical Specialties industry is in the same range as ABT (100). This means that SYK’s stock grew similarly to ABT’s over the last 12 months.
SYK's SMR Rating (52) in the Medical Specialties industry is in the same range as ABT (68). This means that SYK’s stock grew similarly to ABT’s over the last 12 months.
ABT's Price Growth Rating (55) in the Medical Specialties industry is in the same range as SYK (56). This means that ABT’s stock grew similarly to SYK’s over the last 12 months.
ABT's P/E Growth Rating (5) in the Medical Specialties industry is significantly better than the same rating for SYK (83). This means that ABT’s stock grew significantly faster than SYK’s over the last 12 months.
| ABT | SYK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 49% | 1 day ago 58% |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 50% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 46% | 1 day ago 52% |
| TrendWeek ODDS (%) | 1 day ago 54% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 50% |
| Advances ODDS (%) | 7 days ago 56% | 3 days ago 56% |
| Declines ODDS (%) | 2 days ago 56% | 9 days ago 52% |
| BollingerBands ODDS (%) | 1 day ago 55% | 1 day ago 70% |
| Aroon ODDS (%) | 1 day ago 50% | 1 day ago 45% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 1 FA rating(s) are green while SYK’s FA Score has 0 green FA rating(s).
- ABT’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- ABT’s TA Score: 4 bullish, 4 bearish.
- SYK’s TA Score: 4 bullish, 5 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -2.07% price change this week, while SYK (@Medical/Nursing Services) price change was +5.67% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
Reported Earning Dates
ABT is expected to report earnings on Jan 27, 2027.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.